New PIC/S recommendation for evaluating PQS effectiveness in relation to risk-based change management

2 min

On November 28, 2019 the Pharmaceutical Inspection Co-Operation Scheme (PIC/S) published a draft Recommendation for Participating Authorities, providing practical guidance for GMP inspectors, on how to evaluate the effectiveness of a pharmaceutical quality system (PQS) in relation to risk-based change management.(1)

The PIC/S GMP Guide requires companies to have an effective PQS and apply quality risk management (QRM) principles to change control activities.

Chapter 1 states:

· Principle: …there must be ‘a comprehensively designed and correctly implemented Pharmaceutical Quality System incorporating Good Manufacturing Practice and Quality Risk Management. It should be fully documented and its effectiveness monitored’.

· 1.3 ...’the effectiveness of the system is normally demonstrated at the site level’.

· 1.5 ‘Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place...’

· 1.4 (xii) Arrangements [should be] in place ‘for the prospective evaluation of planned changes and their approval prior to implementation…’

Annex 15 states:

· 11.1. ‘The control of change is an important part of knowledge management and should be handled within the pharmaceutical quality system.’

· 11.4. ‘Quality risk management should be used to evaluate planned changes… and to plan for any necessary process validation, verification or requalification efforts.’

· 11.7. ‘…an evaluation of the effectiveness of change should be carried out…’

The recommendation was prepared by the PIC/S Expert Circle on QRM and does not create any new GMP requirements or expectations. It simply provides inspectors with a tool to support an evaluation of PQS effectiveness in relation to risk-based change management. It has been designed to help inspectors increase their understanding of what risk-based change management means at a practical level, and then give a framework to help see how effective implementation might be demonstrated by pharmaceutical companies. The tool provides a checklist approach focusing on:

· Change proposals – Determination of when a change is needed

· Change risk assessments

· Change Planning and implementation

· Change review and effectiveness

The recommendation is currently a draft that is being applied on a 6-month trial basis, with an expectation that formal adoption will subsequently occur on a revised version following comments on use of the tool by PIC/S participating authorities.

Of more significance than the use of the tool by inspectors over the coming months, is that this move starts to see a shift, albeit a small one, towards greater risk-based regulatory oversight as envisaged in ICH Q10 (Pharmaceutical Quality System) and Q12 (Lifecycle Management). (2)



Return to Insights Center

Related Insights


CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024


Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021


U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


EU Orphan Drug Designation – overcoming regulatory challenges

Jul 20, 2022


Preparing for the New Era of Hybrid Regulatory Inspections

Jul 11, 2022


8 things you need to know about eCTDs in China

Jul 1, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022


Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022


New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022


On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022


New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022